Center for the Evaluation of Value and Risk in Health, Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, MA, 02111, USA.
Sarepta Therapeutics, Inc., Cambridge, MA, 02142, USA.
Health Qual Life Outcomes. 2024 Sep 2;22(1):72. doi: 10.1186/s12955-024-02287-2.
Duchenne muscular dystrophy (DMD) is a genetic disease resulting in progressive muscle weakness, loss of ambulation, and cardiorespiratory complications. Direct estimation of health-related quality of life for patients with DMD is challenging, highlighting the need for proxy measures. This study aims to catalog and compare existing published health state utility estimates for DMD and related conditions.
Using two search strategies, relevant utilities were extracted from the Tufts Cost-Effectiveness Analysis Registry, including health states, utility estimates, and study and patient characteristics. Analysis One identified health states with comparable utility estimates to a set of published US patient population utility estimates for DMD. A minimal clinically important difference of ± 0.03 was applied to each DMD utility estimate to establish a range, and the registry was searched to identify other health states with associated utilities that fell within each range. Analysis Two used pre-defined search terms to identify health states clinically similar to DMD. Mapping was based on the degree of clinical similarity.
Analysis One identified 4,308 unique utilities across 2,322 cost-effectiveness publications. The health states captured a wide range of acute and chronic conditions; 34% of utility records were extrapolated for US populations (n = 1,451); 1% were related to pediatric populations (n = 61). Analysis Two identified 153 utilities with health states clinically similar to DMD. The median utility estimates varied among identified health states. Health states similar to the early non-ambulatory DMD phase exhibited the greatest difference between the median estimate of the sample (0.39) and the existing estimate from published literature (0.21).
When available estimates are limited, using novel search strategies to identify utilities of clinically similar conditions could be an approach for overcoming the information gap. However, it requires careful evaluation of the utility instruments, tariffs, and raters (proxy or self).
杜氏肌营养不良症(DMD)是一种遗传性疾病,导致进行性肌肉无力、丧失行动能力以及心肺并发症。直接评估 DMD 患者的健康相关生活质量具有挑战性,这凸显了需要使用替代指标。本研究旨在对现有的 DMD 及相关疾病的发表健康状态效用评估进行分类和比较。
使用两种搜索策略,从 Tufts 成本效益分析登记处提取相关效用,包括健康状态、效用评估以及研究和患者特征。分析一确定了与一组已发表的美国 DMD 患者群体效用评估具有可比效用估计的健康状态。每个 DMD 效用估计值应用最小临床重要差异 ±0.03 来建立一个范围,并在登记处搜索具有相关效用的其他健康状态,这些健康状态的效用落在每个范围内。分析二使用预定义的搜索词来确定与 DMD 临床相似的健康状态。映射基于临床相似程度。
分析一在 2322 项成本效益出版物中确定了 4308 个独特的效用。这些健康状态涵盖了广泛的急性和慢性疾病;34%的效用记录是为美国人群外推的(n=1451);1%与儿科人群有关(n=61)。分析二确定了 153 个与 DMD 临床相似的健康状态具有效用。所确定的健康状态的效用估计中位数差异较大。与早期非步行 DMD 阶段相似的健康状态,其样本中位数估计值(0.39)与已发表文献中的现有估计值(0.21)之间的差异最大。
当可用的估计值有限时,使用新颖的搜索策略来确定临床相似疾病的效用可以作为克服信息差距的一种方法。但是,这需要仔细评估效用工具、关税和评分者(代理或自我)。